Apollo Hospitals has delivered a robust financial performance for the third quarter of the 2026 fiscal year, characterized by a significant surge in profitability and double-digit revenue growth. The healthcare major reported a 35% year-on-year increase in consolidated net profit, reaching 502 crore. This bottom-line growth was supported by a 17% rise in consolidated revenue, which climbed to 6,477 crore compared to the same period last year. Operational efficiency also saw a marked improvement, with EBITDA growing 27% to reach 965 crore. The company’s healthcare services division remains a primary driver of this momentum, posting revenues of 3,183 crore. This 14% increase in the core hospital business was fueled by higher occupancy levels and a shift toward more complex medical cases. Strategic segments like Apollo HealthCo, which integrates pharmacy distribution and digital health, reported a 20% revenue jump to 2,827 crore. Notably, the segment's profitability more than doubled during the quarter, reflecting the maturing of its omni-channel healthcare model. Market performance for the group remains steady, with the stock trading near the 7,220 level. In a move to reward shareholders, the board has declared an interim dividend of 10 per share, with the record date set for February 16, 2026. Beyond the immediate financials, Apollo is executing an aggressive 8,000 crore expansion strategy. The plan aims to add 4,300 beds over the next four years, targeting high-growth markets and under-served Tier 2 and Tier 3 cities. The group recently strengthened its western India presence with the launch of a quaternary care facility in Pune. This facility is part of a broader roadmap to increase total capacity, including new upcoming hospital projects in cities like Kolkata and Hyderabad. The broader Indian healthcare sector is currently supported by a 1.06 lakh crore allocation in the latest Union Budget. Policy focus on "Biopharma Shakti" and the creation of regional medical hubs align with Apollo’s focus on high-end clinical specialties and medical tourism. With an integrated network of over 70 hospitals and 6,800 pharmacies, the company is positioning itself to capture the structural shift in Indian healthcare toward chronic disease management and technology-intensive tertiary care.